These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25979753)

  • 1. EGFR and NF-κB: partners in cancer.
    Shostak K; Chariot A
    Trends Mol Med; 2015 Jun; 21(6):385-93. PubMed ID: 25979753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
    Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
    Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
    Wang DD; Ma L; Wong MP; Lee VH; Yan H
    PLoS One; 2015; 10(5):e0128360. PubMed ID: 25993617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
    Hamed MM; Darwish SS; Herrmann J; Abadi AH; Engel M
    J Med Chem; 2017 Apr; 60(7):2853-2868. PubMed ID: 28291344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
    Bivona TG; Hieronymus H; Parker J; Chang K; Taron M; Rosell R; Moonsamy P; Dahlman K; Miller VA; Costa C; Hannon G; Sawyers CL
    Nature; 2011 Mar; 471(7339):523-6. PubMed ID: 21430781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NF-κB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells.
    Fukuoka M; Yoshioka K; Hohjoh H
    PLoS One; 2018; 13(8):e0201796. PubMed ID: 30075033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
    Gadgeel SM; Ali S; Philip PA; Wozniak A; Sarkar FH
    Cancer; 2009 May; 115(10):2165-76. PubMed ID: 19288574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
    Tartarone A; Lazzari C; Lerose R; Conteduca V; Improta G; Zupa A; Bulotta A; Aieta M; Gregorc V
    Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.
    Kim Y; Apetri M; Luo B; Settleman JE; Anderson KS
    Mol Cancer Res; 2015 Apr; 13(4):765-74. PubMed ID: 25573954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells.
    De S; Dermawan JK; Stark GR
    Proc Natl Acad Sci U S A; 2014 Aug; 111(32):11721-6. PubMed ID: 25071181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.
    Chiu CF; Chang YW; Kuo KT; Shen YS; Liu CY; Yu YH; Cheng CC; Lee KY; Chen FC; Hsu MK; Kuo TC; Ma JT; Su JL
    Proc Natl Acad Sci U S A; 2016 May; 113(18):E2526-35. PubMed ID: 27091996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
    Hu Y; Zang J; Cao H; Wu Y; Yan D; Qin X; Zhou L; Fan F; Ni J; Xu X; Sha H; Liu S; Yu S; Wang Z; Ma R; Wu J; Feng J
    Oncotarget; 2017 Feb; 8(9):15802-15814. PubMed ID: 28178657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.
    Blakely CM; Pazarentzos E; Olivas V; Asthana S; Yan JJ; Tan I; Hrustanovic G; Chan E; Lin L; Neel DS; Newton W; Bobb KL; Fouts TR; Meshulam J; Gubens MA; Jablons DM; Johnson JR; Bandyopadhyay S; Krogan NJ; Bivona TG
    Cell Rep; 2015 Apr; 11(1):98-110. PubMed ID: 25843712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.
    Zou B; Lee VHF; Yan H
    BMC Bioinformatics; 2018 Mar; 19(1):88. PubMed ID: 29514601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells.
    Yang Z; Hu X; Zhang S; Zhang W; Tam KY
    Eur J Pharmacol; 2017 Nov; 815():80-87. PubMed ID: 28870456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of resistance to ErbB-targeted cancer therapeutics.
    Wang Q; Greene MI
    J Clin Invest; 2008 Jul; 118(7):2389-92. PubMed ID: 18568082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
    Quatrale AE; Porcelli L; Silvestris N; Colucci G; Angelo A; Azzariti A
    Front Biosci (Landmark Ed); 2011 Jan; 16(5):1962-72. PubMed ID: 21196276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding resistance to EGFR inhibitors-impact on future treatment strategies.
    Wheeler DL; Dunn EF; Harari PM
    Nat Rev Clin Oncol; 2010 Sep; 7(9):493-507. PubMed ID: 20551942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.